The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry on risperidone injection entitled ``Draft Guidance on Risperidone.'' The recommendations provide specific guidance on the design of studies to support abbreviated new drug applications (ANDAs) for risperidone injection. This draft guidance is the second revision of a previously issued draft guidance on the same subject.
Document
Bioequivalence Recommendations for Risperidone; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry on risperidone injection entitled ``Draft Guidance on Risperidone.'' The r...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
80 FR 30255
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Bioequivalence Recommendations for Risperidone; Draft Guidance for Industry; Availability,” thefederalregister.org (May 27, 2015), https://thefederalregister.org/documents/2015-12847/bioequivalence-recommendations-for-risperidone-draft-guidance-for-industry-availability.